TP53 p.Arg337His in Brazilian lung cancer: when tumour profiling should trigger germline evaluation

Renata Lazari Sandoval

doi:10.1016/j.lana.2026.101569

July 13, 2026The Lancet Regional Health - AmericasOpen Access

TP53 p.Arg337His in Brazilian lung cancer: when tumour profiling should trigger germline evaluation

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to explore the significance of TP53 mutations in lung cancer and the necessity for germline evaluation in affected individuals.
Conducted a large-scale molecular characterization of lung cancer in Brazil.
Analyzed the relationship between TP53 co-mutations and EGFR mutations.
Reviewed supplementary data to evaluate clinical relevance.
Reinforced the clinical importance of broad tumour profiling in lung cancer management.
Identified TP53 mutations as crucial markers that may necessitate germline testing.

Implication

Investigates TP53 mutation implications in lung cancer, suggesting need for germline evaluation.

Abstract

Cavagna and colleagues provide one of the largest real-world molecular characterisations of lung cancer in Brazil, reinforcing the clinical relevance of broad tumour profiling and TP53 co-mutations in EGFR-mutant disease.1 We highlight an additional implication of their supplementary data.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Renata Lazari Sandoval (2026) studied this question.

synapsesocial.com/papers/6a5874242b46c88ba9ad06ce https://doi.org/10.1016/j.lana.2026.101569

View Full Paper

Ask AI

Bookmark

Share

TP53 p.Arg337His in Brazilian lung cancer: when tumour profiling should trigger germline evaluation

Key Points

Implication

Abstract

Discussion

Cite This Study

TP53 p.Arg337His in Brazilian lung cancer: when tumour profiling should trigger germline evaluation

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading